Incyte Corporation (INCY) Earnings Call Transcripts

Incyte Corporation's Latest Earnings Call - Q2 FY2026

Incyte Corporation reported strong second quarter results for 2026, with total revenue of $1.67 billion, reflecting a 38% year-over-year increase. Total net sales reached $1.49 billion, up 40% year-over-year, driven by robust demand across its product portfolio, including a notable contribution from Jakafi and the launch of Jakafi XR. Management raised full-year guidance for total net sales to a range of $5.13 billion to $5.26 billion, indicating confidence in continued growth, particularly in the hematology and oncology segments.

Reported metrics

Guidance from management

Incyte raised its full-year 2026 total net sales guidance to $5.13 billion to $5.26 billion, reflecting strong performance and positive momentum in the hematology and oncology segments. Opzelura's guidance was also updated to $1.05 billion to $1.10 billion, up from previous estimates.

What management said

Yes. Thanks, Jay. Yes, we did get very favorable feedback both from KOLs and importantly, from the patient advocacy channel as well A lot of the discussion was around the impressive clinical profile thus far from latarcibart. But a secondary discussion did emerge around the treatment of bleeds and the urgency to use better prophylaxis to prevent bleeds in a broader set of patients. So coming out of ISTH, absolutely, ...

And Jay, if you think about it, there is a hemophilia A like population in Von Willebrand's brands. And that is a sizable pool of patients who are severe frequent bleeders. And if 039 comes out of Phase III, like David said, with a substantial reduction in the annual bleed rate and a good benefit risk profile, adoption in that group, which could be almost 10,000 people would turn this into one of the largest products...

What analysts pressed on

Analysts expressed concerns regarding the sustainability of growth in the pricing and reimbursement environment, particularly for Opzelura. There were also questions about the regulatory path for the CALR program and the potential impact of the recent acquisition on R&D capacity and focus.

Main topics on the call

• Strong Revenue Growth — Incyte's total revenue for Q2 2026 was $1.67 billion, a 38% increase year-over-year. The growth was attributed to strong demand across the product portfolio and a one-time benefit from a CMS settlement.
• Jakafi Performance — Jakafi sales were $817 million, up 7% year-over-year, with prescription demand increasing by 9%. Management emphasized that Jakafi remains a strategic priority, serving as a funding vehicle for the pipeline.
• Opzelura Growth and Regulatory Updates — Opzelura generated $450 million in sales, including a one-time benefit of $246 million from the CMS settlement. Management expects continued growth and a potential approval for moderate atopic dermatitis in Europe in Q3 ...
• Pipeline Advancements — Incyte advanced multiple assets into late-stage development, including 989 in essential thrombocythemia and 734 in pancreatic cancer. Management highlighted a catalyst-rich second half of 2026 with 10 data readouts expec...

Read the full Incyte Corporation transcript (Q2 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 115 Incyte Corporation earnings call transcripts on record, spanning January 2, 2020 to July 28, 2026. Based on this history, Incyte Corporation reports quarterly. The most recent call on file is dated July 28, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

INCY

Exchange

NasdaqGS

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

115

First call

January 2, 2020

Most recent

July 28, 2026

Reporting cadence

quarterly